Based on: Asthma — gene targets, candidate compounds and trials, OSMF Research Tracker (DGIdb, Open Targets, ChEMBL, PubMed and ClinicalTrials.gov data). Numbers are a snapshot taken 8 October 2026; the tracker page is the live version.
Short answer: as of October 2026, the OSMF Research Tracker lists 55 candidate interventions for asthma that are either approved medicines or have at least one registered clinical trial, built on 15 druggable gene targets, with 14 recent trials on ClinicalTrials.gov. 7 are already approved medicines, for this condition or another one; where the approval is for a different condition, the trial is testing a new use, which is what drug repurposing means. Being in a trial says an intervention is being studied, not that it works; that is what the trial is for.
Which candidates have the most trial activity?
Ranked by the number of registered trials the tracker found. Each trial ID links to the registry entry, where you can read the design, status and sponsor.
- Mometasone furoate — 2 registered trials · approved medicine · NCT00835094
- BENRALIZUMAB — 1 registered trial · approved medicine · NCT04742504
- Budesonide — 1 registered trial · approved medicine · NCT01676987
- Fluticasone furoate — 1 registered trial · approved medicine · NCT01159912
- Fluticasone propionate — 1 registered trial · approved medicine · NCT01159912
- Formoterol Fumarate — 1 registered trial · approved medicine · NCT00215371
- montelukast — 1 registered trial · approved medicine · NCT01156792
- Active booster — 1 registered trial · investigational · NCT06612294
- Administration of inhaled tiotropium bromide — 1 registered trial · investigational · NCT00557700
- AER 001 — 1 registered trial · investigational · NCT00535028
- Alfacalcidol — 1 registered trial · investigational · NCT02747381
- AMAZE™ Application — 1 registered trial · investigational · NCT04868500
Which gene targets are these built on?
The tracker starts from genes with evidence of being druggable in asthma and asks which compounds act on them. Each symbol links to its DGIdb entry, which lists the interacting drugs and the papers behind them: ADRB2, ALOX5, CYSLTR1, FCER1A, GATA3, IL13, IL13RA1, IL1RL1, IL33, IL4, IL4R, IL5, IL5RA, MS4A2, TSLP.
Which trials are registered?
- Agricultural Health Study Follow-up NCT01399411 · Completed · started 2011-07-05
- Effect of Multimedia Protocol About Asthma Control NCT06974331 · Completed · Phase NA · started 2024-09-01
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations NCT06052267 · Active Not Recruiting · Phase PHASE3 · started 2023-08-30
- A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma NCT07219173 · Recruiting · Phase PHASE2 · started 2025-10-22
- Withdrawal of Dupilumab in Severe Asthma NCT06818019 · Recruiting · Phase PHASE4 · started 2025-12-15
- Role of Genetic Factors in the Development of Lung Disease NCT00001532 · Recruiting · started 1996-09-13
- TGF-(Beta) and Susceptibility to RSV NCT01224691 · Completed · started 2012-03-19
- Effects of Swedish Massage Prior Circuit Breathing Training on Asthma NCT06407011 · Completed · Phase NA · started 2024-05-05
- Long-term Effect of Dupilumab in N-ERD NCT07049978 · Completed · started 2025-09-01
- A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) NCT07276724 · Recruiting · Phase PHASE3 · started 2025-12-03
How to read this
Evidence is graded on the tracker page in three tiers: clinical (tested in people), mechanistic (a documented action on the target) and correlative (an association in the literature). Most candidates sit in the lower tiers, and many trials are small or early-phase. The purpose of this list is to show where the research is, with sources, so that patients, clinicians and researchers can look further; it is not a ranking of what to take.
Related on this site
Research information, not medical advice. Decisions about any medicine belong with you and your clinician. The underlying data are open (CC BY 4.0) and refreshed daily; this note was generated from the tracker page on 8 October 2026.